Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2007
10/30/2007US7288568 Alzheimer's disease; Parkinson's disease; inflammatory bowel disease; antiarthritic agents
10/30/2007US7288567 Inhibitors of histone deacetylase
10/30/2007US7288566 Inhibit 20-hydroxyeicosatetraenoic acid (20-HETE)-producing enzymes; kidney disease
10/30/2007US7288565 Azasugar compound
10/30/2007US7288564 Analgesics, antiinflammatory agents, autoimmune diseases, bone disorders, central nervous system disorders
10/30/2007US7288563 modulators of monocyte chemotactic proteins MCP-1 receptor; inflammatory diseases such as asthma and allergies, autoimmune diseases such as rheumatoid arthritis and atherosclerosis
10/30/2007US7288562 treating diseases or disorders of the respiratory, urinary and gastrointestinal systems
10/30/2007US7288561 Such as N,N-dimethyl-3-(phenylsulfonyl)-6,7,8,9-tetrahydro-3H-benzo[e]indol-8-amine; for treatment of central nervous system disorders related to or affected by serotonin receptor antagonists such as neurodegenerative disorders, attention deficit disorder, obsessive compulsive disorder, and drug abuse
10/30/2007US7288560 Spirocyclic cyclohexane derivatives
10/30/2007US7288559 Carboxamide spirohydantoin CGRP receptor antagonists
10/30/2007US7288558 Pharmaceutical composition for treatment for urinary diseases comprising LPA receptor regulator
10/30/2007US7288557 Triazole derivatives
10/30/2007US7288556 Antiproliferative 1,2,3-thiadiazole compounds
10/30/2007US7288554 For agriculture crops
10/30/2007US7288553 Indole derivatives as selective androgen receptor modulator (SARMS)
10/30/2007US7288552 Such as 4-[4-(benzhydryloxy)piperidino]butyl-4-nitrobenzoate
10/30/2007US7288551 For storing and perfusing a heart intended for transplantation; cyclosporin preserves the mitochondrial function by maintaining ATP levels, and blocks apoptosis
10/30/2007US7288550 Administering 2-butyl-1-[5-(methylsulfonyl)pentyl]-1H-imidazo[4,5-c]quinolin-4-amine or salts to induce biosynthesis of cytokines such as IFN- alpha and/or TNF- alpha; treating viral diseases
10/30/2007US7288549 Heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents
10/30/2007US7288548 Spiro compounds and methods for the modulation of chemokine receptor activity
10/30/2007US7288547 CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents
10/30/2007US7288546 Reacting protein with 5-{5-(2-nitro-phenyl)-furan-2-ylmethylene}-1,3-diphenyl-2-thioxo-dihydropyrimidine-4,6-dione
10/30/2007US7288545 e.g., 3-[(5-benzyloxypyridin-2-yl)methylidene]-6-phenylmethylidene piperazine-2,5-dione; treating an angiogenesis-related disease.
10/30/2007US7288544 Calcium channel antagonistic activity; especially useful as analgesics
10/30/2007US7288543 Opioid receptor antagonists
10/30/2007US7288542 viricides; therapy for genetic engineered virus; polymerase inhibitor
10/30/2007US7288541 Propylcarbamate derivatives as inhibitors of serine and cysteine proteases
10/30/2007US7288540 Phenylalkynes
10/30/2007US7288538 Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists
10/30/2007US7288537 Azetidine derivatives as CCR-3 receptor antagonists
10/30/2007US7288536 For therapy of skin diseases such as eczema, psoriasis, allergic dermatitis neurodermatitis, pruritis and hypersensitivity reactions; inflammatory conditions of the nose, throat or lungs such as asthma (including allergen-induced asthmatic reactions), rhinitis (including hayfever), nasal polyps
10/30/2007US7288535 Methods and compositions for stimulating bone growth using nitric oxide releasing bisphosphonate conjugates
10/30/2007US7288534 Sphingomyelin enhancement of tumor therapy
10/30/2007US7288533 Using a dioxaborinane compound
10/30/2007US7288530 Cancer therapy
10/30/2007US7288529 ALK protein tyrosine kinase, cells and methods embodying and using same
10/30/2007US7288528 Aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
10/30/2007US7288527 Inhibition of allergic contact dermatitis by N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester
10/30/2007US7288517 Especially treating Alzheimer's disease with cetrorelix.
10/30/2007US7288280 Complete feed for fish larvae and method for preparing same
10/30/2007US7288271 Chlorogenic acid and an analog thereof for immune system stimulation
10/30/2007US7288267 Bioadhesive nanoparticulate compositions having cationic surface stabilizers
10/30/2007US7288262 Composition comprising a cyclohexane-based compound, compound and use of said compound to structure a composition
10/30/2007US7288251 Antibodies to CD40
10/30/2007US7288246 Method of alleviating chronic pain via peripheral glutaminase regulation
10/30/2007US7288243 Aerosol drug inhibition of lung metastases
10/30/2007US7287646 Diagnosis and treatment of cervical and bladder cancer; improved photochemotherapeutic properties; antineoplastic agents
10/30/2007CA2509650C C-6 modified indazolylpyrrolotriazines
10/30/2007CA2451433C Oligopeptide transporter 1 inhibitor
10/30/2007CA2421548C Amidine inhibitors of serine proteases
10/30/2007CA2416212C Indole derivatives useful for the treatment of cns disorders
10/30/2007CA2382106C Steroids, their preparation, pharmaceutical compositions thereof and uses of the compounds
10/30/2007CA2340214C Method of manufacture of 1,3-oxathiolane nucleosides
10/30/2007CA2335280C Method of treating pulmonary hypertension
10/30/2007CA2330424C Improved method for eradication of helicobacter pylori
10/30/2007CA2329232C Stable compositions comprising levosimendan and alginic acid
10/30/2007CA2328703C Delavirdine tablet formulation
10/30/2007CA2320627C Medicament for treatment of diastolic dysfunction
10/30/2007CA2297083C Pharmaceutical compositions containing lysostaphin alone or in combination with an antibiotic for the treatment of staphylococcal infections
10/30/2007CA2286552C Aminosugar, glycosaminoglycan or glycosaminoglycan-like compounds, and s-adenosylmethionine
10/30/2007CA2276287C Screening method for compounds active in treating myopia and hypermetropia
10/30/2007CA2272701C Glycolipid mimics and methods of use thereof
10/30/2007CA2264002C Naphthyl compounds, intermediates, compositions, and methods of use
10/30/2007CA2245533C Conjugated linoleic acids for attenuating the allergic response
10/30/2007CA2239227C Nitrogen-containing heterocyclic compounds
10/30/2007CA2231588C Process for the preparation of 4-(4-(4-(hydroxydiphenyl)-1-piperidinyl)-1-hydroxybutyl)-.alpha.,.alpha.-dimethylphenylacetic acid and phosphorylated derivatives
10/30/2007CA2220012C Methods for modulating t cell survival by modulating bcl-xl protein level
10/30/2007CA2219802C Anti-emetic pharmaceutical compositions containing methotrimeprazine
10/30/2007CA2216583C Levobupivacaine and its use as an anaesthetic in pregnant women
10/30/2007CA2206995C Use of alkanoyl l-carnitines for the therapeutical treatment of chronic inflammatory bowel diseases
10/30/2007CA2186760C Use of biopolymers for the muscle treatment
10/30/2007CA2186757C Use of biopolymers for digestive tract injuries treatment
10/30/2007CA2179650C Bisindolemaleimides and their use as protein kinase c inhibitors
10/30/2007CA2164291C Methods and pharmaceutical compositions useful for treating neurological disorders
10/30/2007CA2136140C Carcinostatic for hormonotherapy containing dienogest as effective component
10/30/2007CA1341560C Recombinant dna-derived bordetella toxin subunit analogs
10/26/2007WO2007127630A1 Controlled released preparations of oxcarbazepine having sigmoidal release profile
10/26/2007CA2586392A1 A method for alleviating signs and symptoms of spasticity
10/25/2007WO2007121483A2 Pre-mixed, ready-to-use iv bolus compositions and methods of use
10/25/2007WO2007121481A2 Pyridone sulfonamides and pyridone sulfamides as mek inhibitors
10/25/2007WO2007121479A2 Methods and compositions for treating barth syndrome, cardiomyopathy, mitochondrial diseases and other conditions
10/25/2007WO2007121471A2 Dialkyl ether delivery agents
10/25/2007WO2007121453A2 2-hydroxy-1-oxo 1,2 dihydro isoquinoline chelating agents
10/25/2007WO2007121432A2 Benzoazepin-oxy-acetic acid derivatives as ppar-delta agonists used for the increase of hdl-c, lower ldl-c and lower cholesterol
10/25/2007WO2007121418A2 Chemical compounds
10/25/2007WO2007121416A2 Chemical compounds
10/25/2007WO2007121415A2 Chemical compounds
10/25/2007WO2007121389A2 4,4-disubstituted piperidine derivatives as nk-i and serotonin transporter inhibitors
10/25/2007WO2007121356A2 Method of treatment with predictably breakable pharmaceutical tablets
10/25/2007WO2007121352A2 Therapeutic triterpenoids
10/25/2007WO2007121339A2 Process for the preparation of indazolyl ureas that inhibit vanilloid subtype 1 (vr1) receptors
10/25/2007WO2007121312A2 Trivalent chromium compounds, compositions and methods of use
10/25/2007WO2007121299A2 Antagonists of the vanilloid receptor subtype 1 (vr1) and uses thereof
10/25/2007WO2007121280A1 2,6-substituted-4-monosubstituted amino-pyrimidine as prostaglandin d2 receptor antagonists
10/25/2007WO2007121279A2 Cancer treatment method
10/25/2007WO2007121269A2 N-aryl-n'alkyl sulfamides as mek inhibitors
10/25/2007WO2007121188A2 Compositions and methods of using r(+) pramipexole
10/25/2007WO2007121154A2 Substituted benzothiazole kinase inhibitors
10/25/2007WO2007120972A2 Method to treat sickle cell disease
10/25/2007WO2007120936A2 Use.of vildagliptin for the treatment of diabetes
1 ... 3526 3527 3528 3529 3530 3531 3532 3533 3534 3535 3536 3537 3538 3539 3540 3541 3542 3543 3544 3545 3546 ... 7860